A detailed history of China Universal Asset Management Co., Ltd. transactions in Atea Pharmaceuticals, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 16,237 shares of AVIR stock, worth $51,796. This represents 0.01% of its overall portfolio holdings.

Number of Shares
16,237
Previous 9,894 64.11%
Holding current value
$51,796
Previous $32,000 68.75%
% of portfolio
0.01%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$3.17 - $4.02 $20,107 - $25,498
6,343 Added 64.11%
16,237 $54,000
Q2 2024

Jul 19, 2024

SELL
$3.31 - $4.04 $20,803 - $25,391
-6,285 Reduced 38.85%
9,894 $32,000
Q1 2024

Apr 29, 2024

BUY
$3.09 - $4.56 $20,165 - $29,758
6,526 Added 67.61%
16,179 $65,000
Q4 2023

May 21, 2024

SELL
$2.8 - $3.35 $18,272 - $21,862
-6,526 Reduced 40.34%
9,653 $29,000
Q4 2023

Jan 23, 2024

BUY
$2.8 - $3.35 $21,039 - $25,171
7,514 Added 351.29%
9,653 $29,000
Q3 2023

May 21, 2024

BUY
$3.0 - $3.79 $3,138 - $3,964
1,046 Added 95.7%
2,139 $6,000
Q3 2023

Oct 30, 2023

BUY
$3.0 - $3.79 $3,138 - $3,964
1,046 Added 95.7%
2,139 $6,000
Q2 2023

May 21, 2024

SELL
$3.21 - $5.06 $115 - $182
-36 Reduced 3.19%
1,093 $4,000
Q2 2023

Jul 27, 2023

SELL
$3.21 - $5.06 $115 - $182
-36 Reduced 3.19%
1,093 $4,000
Q1 2023

May 21, 2024

BUY
$3.0 - $4.97 $849 - $1,406
283 Added 33.45%
1,129 $3,000
Q1 2023

Apr 27, 2023

BUY
$3.0 - $4.97 $849 - $1,406
283 Added 33.45%
1,129 $4,000
Q4 2022

May 21, 2024

SELL
$4.35 - $6.17 $66,698 - $94,604
-15,333 Reduced 94.77%
846 $4,000
Q4 2022

Jan 31, 2023

BUY
$4.35 - $6.17 $287 - $407
66 Added 8.46%
846 $4,000
Q3 2022

Oct 21, 2022

BUY
$5.49 - $8.79 $4,282 - $6,856
780 New
780 $4,000

Others Institutions Holding AVIR

About Atea Pharmaceuticals, Inc.


  • Ticker AVIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 83,258,600
  • Market Cap $266M
  • Description
  • Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...
More about AVIR
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.